Dragan Grabulovski
CEO Araris Biotech
Dragan is a co-founder and CEO of Araris. He has been a member of the company’s board of directors since its inception. Prior to this role, he worked as a biotech consultant, advising numerous venture capital firms and biotech companies, and served as a start-up coach for ETH Zurich and Innosuisse. From 2007 to 2014, he was the co-founder and CSO of Covagen, a Swiss biotech company that was acquired in 2014 by an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. Dragan holds a Master’s degree and a PhD in Pharmaceutical Sciences from ETH Zurich.
Seminars
Tuesday 9th March 2027
CEO & ADC Pharma Leaders Think Tank: Solidifying Next-Generation ADCs as Standard of Care Therapies
9:00 am
- Outlining the latest trends across the ADC landscape in 2027 and future vision to develop and deliver novel ADCs with meaningful patient impact with safety and efficacy
- Highlighting methods to best pursue ADC clinical differentiation across patient selection technologies, combination strategies, and well-executed clinical design
- With clinical trials advancing in the Far East and Australia, what opportunities does this open for the ADC industry to progress faster?
Wednesday 10th March 2027
Precision Conjugation: One Antibody, One Step, Multiple Payloads
11:45 am
- Presenting AraLinQ™ ADCs: ADCs targeting solid and liquid tumours, including clinical-stage ARC-02
- Highlighting Efficacy and Tolerability: Preclinical data demonstrating strong anti-tumour efficacy and high tolerability across multiple models
- Overcoming conventional ADC limitations: Addressing payload loss and narrow therapeutic windows through differentiated ADC design and multi payload approaches
